Pharsight

Entereg generic

Entereg is a drug used to accelerate gastrointestinal recovery. The active ingredient is alvimopan and it is owned by Cubist Pharms. Entereg was first authorized for market use on 20 May, 2008.

When will Entereg generic be available?

The generic version of Entereg might be available after 12 February, 2030. This is due to the expiration of the last patent held by Cubist Pharms. The patent, titled 'Methods of preventing and treating gastrointestinal dysfunction', expires on 2030-02-12.

Entereg uses

Entereg is used to accelerate the time to gastrointestinal recovery. Its active ingredient, alvimopan, is administered to the patient from about 30 to 60 minutes prior to surgery, aiding in faster recovery.

Entereg patent expiration

Entereg has a total of 1 drug patent, with the last one due to expire on 2030-02-12. This patent, titled 'Methods of preventing and treating gastrointestinal dysfunction', will define when the Entereg generic will become available. Below are the details of the patent:

Entereg dosage

Want to ask something?